ALS-8112 is an investigational antiviral nucleoside analog primarily developed for the treatment of chronic hepatitis C virus (HCV) infections. It is phosphorylated intracellularly to its active triphosphate form, ALS-8112-TP, which selectively inhibits the HCV NS5B RNA-dependent RNA polymerase, thereby blocking viral RNA replication. This mechanism makes it a promising candidate for anti-HCV therapy, particularly against genotype 1. Preclinical and Phase I clinical studies have demonstrated potent antiviral activity and a favorable safety profile, with ongoing research evaluating its efficacy in combination regimens and potential for broader clinical use.